Swedish research-based biopharma company BioArctic AB (STO:BIOA-B) announced on Thursday that its royalties from first-quarter 2025 global sales of Leqembi (lecanemab), developed in partnership with Eisai Co Ltd (TYO:4523), totalled SEK101.7m

This represents an increase of approximately 380% compared to the same period in 2024.

Eisai reported preliminary global Leqembi revenue of JPY14.7bn in conjunction with its partner Biogen's (NASDAQ:BIIB) first-quarter earnings.

Leqembi is a monoclonal antibody targeting aggregated amyloid-beta and is approved for treating early-stage Alzheimer's disease in multiple global markets. The therapy was developed under a strategic alliance between BioArctic and Eisai, with clinical approval driven by positive Phase 3 Clarity AD trial results.

In January 2025 the US Food and Drug Administration (FDA) approved a supplemental Biologics License Application for intravenous maintenance dosing. The agency also accepted a Biologics License Application for a weekly subcutaneous autoinjector, with a Prescription Drug User Fee Act action date set for 31 August 2025.

BioArctic will release its full Q1 2025 report on 21 May.

(EUR1=SEK11.01)